This study is in progress, not accepting new patients
Study of HPN424 in Patients With Advanced Prostate Cancer
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Lawrence Fong
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Lawrence Fong
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Harpoon Therapeutics
- ID
- NCT03577028
- Phase
- Phase 1/2 Prostate Cancer Research Study
- Study Type
- Interventional
- Participants
- Expecting 110 study participants
- Last Updated